{"pmid":32344469,"title":"DIC in COVID-19: Implications for Prognosis and Treatment?","text":["DIC in COVID-19: Implications for Prognosis and Treatment?","The ongoing COVID-19 pandemic is an exceptional challenge for the health systems throughout the world. So far, no causative therapy nor protective vaccines are available. In several countries, the capacities for intensive care and for support in case of acute respiratory distress syndrome (ARDS) are overstretched, and the mortality is considerable. In this situation, useful prognostic parameters and targeted supportive treatment are urgently needed.","J Thromb Haemost","Seitz, Rainer","Schramm, Wolfgang","32344469"],"abstract":["The ongoing COVID-19 pandemic is an exceptional challenge for the health systems throughout the world. So far, no causative therapy nor protective vaccines are available. In several countries, the capacities for intensive care and for support in case of acute respiratory distress syndrome (ARDS) are overstretched, and the mortality is considerable. In this situation, useful prognostic parameters and targeted supportive treatment are urgently needed."],"journal":"J Thromb Haemost","authors":["Seitz, Rainer","Schramm, Wolfgang"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32344469","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/jth.14878","topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666138495029084160,"score":9.490897,"similar":[{"pmid":32434788,"title":"COVID-19 and lung cancer: risks, mechanisms and treatment interactions.","text":["COVID-19 and lung cancer: risks, mechanisms and treatment interactions.","Cases of the 2019 novel coronavirus also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to rise worldwide. To date, there is no effective treatment. Clinical management is largely symptomatic, with organ support in intensive care for critically ill patients. The first phase I trial to test the efficacy of a vaccine has recently begun, but in the meantime there is an urgent need to decrease the morbidity and mortality of severe cases. It is known that patients with cancer are more susceptible to infection than individuals without cancer because of their systemic immunosuppressive state caused by the malignancy and anticancer treatments. Therefore, these patients might be at increased risk of pulmonary complications from COVID-19. The SARS-CoV-2 could in some case induce excessive and aberrant non-effective host immune responses that are associated with potentially fatal severe lung injury and patients can develop acute respiratory distress syndrome (ARDS). Cytokine release syndrome and viral ARDS result from uncontrolled severe acute inflammation. Acute lung injury results from inflammatory monocyte and macrophage activation in the pulmonary luminal epithelium which lead to a release of proinflammatory cytokines including interleukin (IL)-6, IL-1 and tumor necrosis factor-alpha. These cytokines play a crucial role in immune-related pneumonitis, and could represent a promising target when the infiltration is T cell predominant or there are indirect signs of high IL-6-related inflammation, such as elevated C-reactive protein. A monoclonal anti-IL-6 receptor antibody, tocilizumab has been administered in a number of cases in China and Italy. Positive clinical and radiological outcomes have been reported. These early findings have led to an ongoing randomized controlled clinical trial in China and Italy. While data from those trials are eagerly awaited, patients' management will continue to rely for the vast majority on local guidelines. Among many other aspects, this crisis has proven that different specialists must join forces to deliver the best possible care to patients.","J Immunother Cancer","Addeo, Alfredo","Obeid, Michel","Friedlaender, Alex","32434788"],"abstract":["Cases of the 2019 novel coronavirus also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to rise worldwide. To date, there is no effective treatment. Clinical management is largely symptomatic, with organ support in intensive care for critically ill patients. The first phase I trial to test the efficacy of a vaccine has recently begun, but in the meantime there is an urgent need to decrease the morbidity and mortality of severe cases. It is known that patients with cancer are more susceptible to infection than individuals without cancer because of their systemic immunosuppressive state caused by the malignancy and anticancer treatments. Therefore, these patients might be at increased risk of pulmonary complications from COVID-19. The SARS-CoV-2 could in some case induce excessive and aberrant non-effective host immune responses that are associated with potentially fatal severe lung injury and patients can develop acute respiratory distress syndrome (ARDS). Cytokine release syndrome and viral ARDS result from uncontrolled severe acute inflammation. Acute lung injury results from inflammatory monocyte and macrophage activation in the pulmonary luminal epithelium which lead to a release of proinflammatory cytokines including interleukin (IL)-6, IL-1 and tumor necrosis factor-alpha. These cytokines play a crucial role in immune-related pneumonitis, and could represent a promising target when the infiltration is T cell predominant or there are indirect signs of high IL-6-related inflammation, such as elevated C-reactive protein. A monoclonal anti-IL-6 receptor antibody, tocilizumab has been administered in a number of cases in China and Italy. Positive clinical and radiological outcomes have been reported. These early findings have led to an ongoing randomized controlled clinical trial in China and Italy. While data from those trials are eagerly awaited, patients' management will continue to rely for the vast majority on local guidelines. Among many other aspects, this crisis has proven that different specialists must join forces to deliver the best possible care to patients."],"journal":"J Immunother Cancer","authors":["Addeo, Alfredo","Obeid, Michel","Friedlaender, Alex"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32434788","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1136/jitc-2020-000892","keywords":["t-lymphocytes","immunity","lung neoplasms"],"locations":["Cytokine","China","Italy","China","Italy"],"countries":["China","Italy"],"countries_codes":["CHN|China","ITA|Italy"],"e_drugs":["tocilizumab"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667521393731829760,"score":93.54225},{"pmid":32363221,"pmcid":"PMC7194867","title":"An overview of coronaviruses including the SARS-2 coronavirus - Molecular biology, epidemiology and clinical implications.","text":["An overview of coronaviruses including the SARS-2 coronavirus - Molecular biology, epidemiology and clinical implications.","Coronavirus infections have emerged as epidemic and pandemic threats in last two decades. After the H1N1 influenza pandemic in 2009, recently diagnosed novel betacoronavirus or severe acute respiratory syndrome coronavirus (SARS-CoV)-2 has spread across 203 countries and territories in all 5 major continents. World Health Organization (WHO) declared this as a public health emergency of international concern on January 30, 2020. Subsequently on February 11, 2020 a new name was given to this disease i.e. COVID-19 by an expert group from WHO. As of April 12, 2020, 10:00 CET, GMT+2:00, 1,696,588 confirmed cases and 105,952 confirmed deaths have been reported to the WHO. (Coronavirus disease 2019, situation report 83). It possibly originated from a small animal market in Wuhan, China. A cluster of patients were admitted with unusual pneumonia not responding to treatment in various hospitals. Epidemiological, genomic analysis and correlation with other coronaviruses led to the isolation of new coronavirus, closely resembling the bat coronaviruses, from such patients in Wuhan. They were identified as the SARS-CoV-2. This virus infection presents as influenza like illness in the affected people. Fever, cough, respiratory distress with fatigue, diarrhea, nausea and vomiting are common symptoms seen in adults. This may progress on to respiratory distress, hypoxia, need for oxygen supplementation and ventilator support as seen in patients in the SARS-CoV-1 epidemic (2003) in Guangdong, China. The transmissibility of SARS-CoV-1 was less as compared to SARS-CoV-2 infection, and it was well controlled with good public health efforts. The present COVID-19 epidemic is still in the acceleration phase of 3 and 4 in various countries. Without any effective antiviral agents available at present, the need of the hour is early case detection, isolation of cases, use of good preventive care measures by the household contacts and in the hospital set up. The results of ongoing clinical trials on hydroxychloroquine, azithromycin alone or in combination and a new antiviral agent remdesivir may help to treat some of the infections. A need for effective vaccine is being seen an as good preventive strategy in this pandemic. However the results of clinical trials and incorporation of vaccines in public health programs is a long way to go.","Curr Med Res Pract","Kaul, Dinesh","32363221"],"abstract":["Coronavirus infections have emerged as epidemic and pandemic threats in last two decades. After the H1N1 influenza pandemic in 2009, recently diagnosed novel betacoronavirus or severe acute respiratory syndrome coronavirus (SARS-CoV)-2 has spread across 203 countries and territories in all 5 major continents. World Health Organization (WHO) declared this as a public health emergency of international concern on January 30, 2020. Subsequently on February 11, 2020 a new name was given to this disease i.e. COVID-19 by an expert group from WHO. As of April 12, 2020, 10:00 CET, GMT+2:00, 1,696,588 confirmed cases and 105,952 confirmed deaths have been reported to the WHO. (Coronavirus disease 2019, situation report 83). It possibly originated from a small animal market in Wuhan, China. A cluster of patients were admitted with unusual pneumonia not responding to treatment in various hospitals. Epidemiological, genomic analysis and correlation with other coronaviruses led to the isolation of new coronavirus, closely resembling the bat coronaviruses, from such patients in Wuhan. They were identified as the SARS-CoV-2. This virus infection presents as influenza like illness in the affected people. Fever, cough, respiratory distress with fatigue, diarrhea, nausea and vomiting are common symptoms seen in adults. This may progress on to respiratory distress, hypoxia, need for oxygen supplementation and ventilator support as seen in patients in the SARS-CoV-1 epidemic (2003) in Guangdong, China. The transmissibility of SARS-CoV-1 was less as compared to SARS-CoV-2 infection, and it was well controlled with good public health efforts. The present COVID-19 epidemic is still in the acceleration phase of 3 and 4 in various countries. Without any effective antiviral agents available at present, the need of the hour is early case detection, isolation of cases, use of good preventive care measures by the household contacts and in the hospital set up. The results of ongoing clinical trials on hydroxychloroquine, azithromycin alone or in combination and a new antiviral agent remdesivir may help to treat some of the infections. A need for effective vaccine is being seen an as good preventive strategy in this pandemic. However the results of clinical trials and incorporation of vaccines in public health programs is a long way to go."],"journal":"Curr Med Res Pract","authors":["Kaul, Dinesh"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32363221","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.cmrp.2020.04.001","keywords":["betacoronavirues","covid-19","coronaviruses","sars-cov-1","sars-cov-2","wuhan"],"locations":["Wuhan","China","Wuhan","fatigue","diarrhea","hypoxia","Guangdong","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Hydroxychloroquine","remdesivir","Azithromycin"],"topics":["Treatment","Mechanism","Diagnosis","Prevention"],"weight":1,"_version_":1666138495959171074,"score":92.787506},{"pmid":32367170,"pmcid":"PMC7197634","title":"High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study.","text":["High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study.","PURPOSE: Little evidence of increased thrombotic risk is available in COVID-19 patients. Our purpose was to assess thrombotic risk in severe forms of SARS-CoV-2 infection. METHODS: All patients referred to 4 intensive care units (ICUs) from two centers of a French tertiary hospital for acute respiratory distress syndrome (ARDS) due to COVID-19 between March 3rd and 31st 2020 were included. Medical history, symptoms, biological data and imaging were prospectively collected. Propensity score matching was performed to analyze the occurrence of thromboembolic events between non-COVID-19 ARDS and COVID-19 ARDS patients. RESULTS: 150 COVID-19 patients were included (122 men, median age 63 [53; 71] years, SAPSII 49 [37; 64] points). Sixty-four clinically relevant thrombotic complications were diagnosed in 150 patients, mainly pulmonary embolisms (16.7%). 28/29 patients (96.6%) receiving continuous renal replacement therapy experienced circuit clotting. Three thrombotic occlusions (in 2 patients) of centrifugal pump occurred in 12 patients (8%) supported by ECMO. Most patients (> 95%) had elevated D-dimer and fibrinogen. No patient developed disseminated intravascular coagulation. Von Willebrand (vWF) activity, vWF antigen and FVIII were considerably increased, and 50/57 tested patients (87.7%) had positive lupus anticoagulant. Comparison with non-COVID-19 ARDS patients (n = 145) confirmed that COVID-19 ARDS patients (n = 77) developed significantly more thrombotic complications, mainly pulmonary embolisms (11.7 vs. 2.1%, p < 0.008). Coagulation parameters significantly differed between the two groups. CONCLUSION: Despite anticoagulation, a high number of patients with ARDS secondary to COVID-19 developed life-threatening thrombotic complications. Higher anticoagulation targets than in usual critically ill patients should therefore probably be suggested.","Intensive Care Med","Helms, Julie","Tacquard, Charles","Severac, Francois","Leonard-Lorant, Ian","Ohana, Mickael","Delabranche, Xavier","Merdji, Hamid","Clere-Jehl, Raphael","Schenck, Malika","Fagot Gandet, Florence","Fafi-Kremer, Samira","Castelain, Vincent","Schneider, Francis","Grunebaum, Lelia","Angles-Cano, Eduardo","Sattler, Laurent","Mertes, Paul-Michel","Meziani, Ferhat","32367170"],"abstract":["PURPOSE: Little evidence of increased thrombotic risk is available in COVID-19 patients. Our purpose was to assess thrombotic risk in severe forms of SARS-CoV-2 infection. METHODS: All patients referred to 4 intensive care units (ICUs) from two centers of a French tertiary hospital for acute respiratory distress syndrome (ARDS) due to COVID-19 between March 3rd and 31st 2020 were included. Medical history, symptoms, biological data and imaging were prospectively collected. Propensity score matching was performed to analyze the occurrence of thromboembolic events between non-COVID-19 ARDS and COVID-19 ARDS patients. RESULTS: 150 COVID-19 patients were included (122 men, median age 63 [53; 71] years, SAPSII 49 [37; 64] points). Sixty-four clinically relevant thrombotic complications were diagnosed in 150 patients, mainly pulmonary embolisms (16.7%). 28/29 patients (96.6%) receiving continuous renal replacement therapy experienced circuit clotting. Three thrombotic occlusions (in 2 patients) of centrifugal pump occurred in 12 patients (8%) supported by ECMO. Most patients (> 95%) had elevated D-dimer and fibrinogen. No patient developed disseminated intravascular coagulation. Von Willebrand (vWF) activity, vWF antigen and FVIII were considerably increased, and 50/57 tested patients (87.7%) had positive lupus anticoagulant. Comparison with non-COVID-19 ARDS patients (n = 145) confirmed that COVID-19 ARDS patients (n = 77) developed significantly more thrombotic complications, mainly pulmonary embolisms (11.7 vs. 2.1%, p < 0.008). Coagulation parameters significantly differed between the two groups. CONCLUSION: Despite anticoagulation, a high number of patients with ARDS secondary to COVID-19 developed life-threatening thrombotic complications. Higher anticoagulation targets than in usual critically ill patients should therefore probably be suggested."],"journal":"Intensive Care Med","authors":["Helms, Julie","Tacquard, Charles","Severac, Francois","Leonard-Lorant, Ian","Ohana, Mickael","Delabranche, Xavier","Merdji, Hamid","Clere-Jehl, Raphael","Schenck, Malika","Fagot Gandet, Florence","Fafi-Kremer, Samira","Castelain, Vincent","Schneider, Francis","Grunebaum, Lelia","Angles-Cano, Eduardo","Sattler, Laurent","Mertes, Paul-Michel","Meziani, Ferhat"],"date":"2020-05-06T11:00:00Z","year":2020,"_id":"32367170","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1007/s00134-020-06062-x","keywords":["ards","covid-19","coagulopathy","lupus anticoagulant","thrombosis"],"locations":["French"],"countries":["France"],"countries_codes":["FRA|France"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666138496224460801,"score":88.20581},{"pmid":32265310,"pmcid":"PMC7144273","title":"Current Status of Cell-Based Therapies for Respiratory Virus Infections: Applicability to COVID-19.","text":["Current Status of Cell-Based Therapies for Respiratory Virus Infections: Applicability to COVID-19.","Severe respiratory consequences of the COVID-19 pandemic have prompted urgent need for novel therapies. Cell-based approaches, primarily using mesenchymal stem (stromal) cells (MSCs), have demonstrated safety and possible efficacy in patients with the acute respiratory distress syndrome (ARDS), although not as yet well studied in respiratory virus-induced ARDS. Limited pre-clinical data suggest that systemic MSC administration can significantly reduce respiratory virus (Influenza strains H5N1 and H9N2)-induced lung injury, however, there are no available data in models of coronavirus respiratory infection.There are a rapidly increasing number of clinical investigations of cell-based therapy approaches for COVID-19. These utilise a range of different cell sources, doses, dosing strategies, and targeted patient populations. To provide a rationale strategy to maximise potential therapeutic use, it is critically important to understand the relevant pre-clinical studies and postulated mechanisms of MSC actions in respiratory virus-induced lung injuries. These are presented along with consideration of current clinical investigations.","Eur Respir J","Khoury, Maroun","Cuenca, Jimena","Cruz, Fernanda F","Figueroa, Fernando E","Rocco, Patricia R M","Weiss, Daniel J","32265310"],"abstract":["Severe respiratory consequences of the COVID-19 pandemic have prompted urgent need for novel therapies. Cell-based approaches, primarily using mesenchymal stem (stromal) cells (MSCs), have demonstrated safety and possible efficacy in patients with the acute respiratory distress syndrome (ARDS), although not as yet well studied in respiratory virus-induced ARDS. Limited pre-clinical data suggest that systemic MSC administration can significantly reduce respiratory virus (Influenza strains H5N1 and H9N2)-induced lung injury, however, there are no available data in models of coronavirus respiratory infection.There are a rapidly increasing number of clinical investigations of cell-based therapy approaches for COVID-19. These utilise a range of different cell sources, doses, dosing strategies, and targeted patient populations. To provide a rationale strategy to maximise potential therapeutic use, it is critically important to understand the relevant pre-clinical studies and postulated mechanisms of MSC actions in respiratory virus-induced lung injuries. These are presented along with consideration of current clinical investigations."],"journal":"Eur Respir J","authors":["Khoury, Maroun","Cuenca, Jimena","Cruz, Fernanda F","Figueroa, Fernando E","Rocco, Patricia R M","Weiss, Daniel J"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32265310","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1183/13993003.00858-2020","topics":["Treatment"],"weight":1,"_version_":1666138491957805056,"score":86.17202},{"pmid":32221983,"title":"Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.","text":["Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.","This article reviews the correlation between angiotensin-converting enzyme 2 (ACE2) and severe risk factors for coronavirus disease 2019 (COVID-19) and the possible mechanisms. ACE2 is a crucial component of the renin-angiotensin system (RAS). The classical RAS ACE-Ang II-AT1R regulatory axis and the ACE2-Ang 1-7-MasR counter-regulatory axis play an essential role in maintaining homeostasis in humans. ACE2 is widely distributed in the heart, kidneys, lungs, and testes. ACE2 antagonizes the activation of the classical RAS system and protects against organ damage, protecting against hypertension, diabetes, and cardiovascular disease. Similar to SARS-CoV, SARS-CoV-2 also uses the ACE2 receptor to invade human alveolar epithelial cells. Acute respiratory distress syndrome (ARDS) is a clinical high-mortality disease, and ACE2 has a protective effect on this type of acute lung injury. Current research shows that the poor prognosis of patients with COVID-19 is related to factors such as sex (male), age (>60 years), underlying diseases (hypertension, diabetes, and cardiovascular disease), secondary ARDS, and other relevant factors. Because of these protective effects of ACE2 on chronic underlying diseases and ARDS, the development of spike protein-based vaccine and drugs enhancing ACE2 activity may become one of the most promising approaches for the treatment of COVID-19 in the future.","J Med Virol","Cheng, Hao","Wang, Yan","Wang, Gui-Qiang","32221983"],"abstract":["This article reviews the correlation between angiotensin-converting enzyme 2 (ACE2) and severe risk factors for coronavirus disease 2019 (COVID-19) and the possible mechanisms. ACE2 is a crucial component of the renin-angiotensin system (RAS). The classical RAS ACE-Ang II-AT1R regulatory axis and the ACE2-Ang 1-7-MasR counter-regulatory axis play an essential role in maintaining homeostasis in humans. ACE2 is widely distributed in the heart, kidneys, lungs, and testes. ACE2 antagonizes the activation of the classical RAS system and protects against organ damage, protecting against hypertension, diabetes, and cardiovascular disease. Similar to SARS-CoV, SARS-CoV-2 also uses the ACE2 receptor to invade human alveolar epithelial cells. Acute respiratory distress syndrome (ARDS) is a clinical high-mortality disease, and ACE2 has a protective effect on this type of acute lung injury. Current research shows that the poor prognosis of patients with COVID-19 is related to factors such as sex (male), age (>60 years), underlying diseases (hypertension, diabetes, and cardiovascular disease), secondary ARDS, and other relevant factors. Because of these protective effects of ACE2 on chronic underlying diseases and ARDS, the development of spike protein-based vaccine and drugs enhancing ACE2 activity may become one of the most promising approaches for the treatment of COVID-19 in the future."],"journal":"J Med Virol","authors":["Cheng, Hao","Wang, Yan","Wang, Gui-Qiang"],"date":"2020-03-30T11:00:00Z","year":2020,"_id":"32221983","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1002/jmv.25785","keywords":["acute respiratory distress syndrome (ards)","angiotensin-converting enzyme 2 (ace2)","coronavirus disease 2019 (covid-19)","renin-angiotensin system (ras)","severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490457292800,"score":85.504585}]}